Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine + Rituximab for relapsed/refractory warm autoimmune hemolytic anemia
ChiCTR2500110686Phase 4Recruiting
- Sponsor
- Suzhou Hongci Hematology Hospital
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bendamustine and rituximab in autoimmune haemolytic anaemia (AIHA), sponsored by Suzhou Hongci Hematology Hospital. Primary endpoint: 2-year recurrence-free survival. Started Mar 2024; status: recruiting.
02
Drugs
bendamustinerituximab
03
Conditions
autoimmune haemolytic anaemia (AIHA)
Beyond the preview
Go deeper on ChiCTR2500110686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110686.